KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 71.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,072 shares of the specialty pharmaceutical company's stock after selling 24,651 shares during the quarter. American Century Companies Inc.'s holdings in KalVista Pharmaceuticals were worth $85,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Intech Investment Management LLC raised its stake in KalVista Pharmaceuticals by 58.5% during the fourth quarter. Intech Investment Management LLC now owns 17,204 shares of the specialty pharmaceutical company's stock worth $146,000 after purchasing an additional 6,349 shares during the period. AlphaQuest LLC lifted its position in shares of KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after purchasing an additional 2,588 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares in the last quarter. SG Americas Securities LLC increased its stake in KalVista Pharmaceuticals by 10.0% during the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after buying an additional 1,319 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in KalVista Pharmaceuticals in the 4th quarter worth $634,000.

KalVista Pharmaceuticals Stock Up 2.2 %

KALV stock traded up $0.26 during trading on Friday, hitting $12.00. 495,506 shares of the company's stock traded hands, compared to its average volume of 403,418. The stock has a fifty day moving average price of $11.32 and a two-hundred day moving average price of $10.31. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The stock has a market capitalization of $596.59 million, a price-to-earnings ratio of -3.30 and a beta of 0.39.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Jones Trading restated a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $24.83.

Insider Activity at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par purchased 100,000 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $9.23 per share, with a total value of $923,000.00. Following the completion of the acquisition, the insider now owns 5,217,285 shares in the company, valued at $48,155,540.55. The trade was a 1.95 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the transaction, the insider now owns 100,334 shares of the company's stock, valued at $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders acquired 261,055 shares of company stock valued at $2,397,646 and sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).